Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Intercept Pharmaceuticals
Biotech
Zydus' phase 3 win tees up filing to challenge Gilead and Ipsen
The win in primary biliary cholangitis clears the path to an FDA filing to establish the company as a challenger to Gilead, Intercept and Ipsen.
Nick Paul Taylor
Aug 29, 2025 10:59am
Lilly inks $50M deal for biotech's FXR program
Feb 26, 2025 5:35am
Ipsen, Genfit report phase 3 rare liver disease success
Jun 30, 2023 6:15am
Enanta pulls plug on NASH, seeks to offload assets for combos
Oct 4, 2021 8:40am
Ex-Intercept CMO Campagna lands at Q32
Mar 9, 2021 8:45am
Intercept loses chief medical officer months after CEO's exit
Feb 23, 2021 7:20am
